Market Overview:
The global myocardial infarction treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of myocardial infarction, rising geriatric population, and technological advancements in the field of myocardial infarction treatment. The global myocardial infarction treatment market is segmented by type into antiplatelet agents, glycoprotein IIb/IIIa inhibitors, antithrombotic agents, and others. The antiplatelet agents segment is expected to dominate the market during the forecast period owing to its high usage in preventing thrombus formation. The glycoprotein IIb/IIIa inhibitors segment is projected to grow at a higher CAGR during the forecast period due its ability to reduce mortality rates and improve patient outcomes. The global myocardial infarction treatment market is also segmented by application into hospital and clinic settings. The hospital setting accounted for majority of the share in 2017 owingtoits large patient base and better infrastructure for providing care facilities such as ICUsand cardiac wards .
Product Definition:
Myocardial infarction treatment, also known as heart attack treatment, is the medical care given to a person who has suffered a myocardial infarction, or heart attack. The main goal of myocardial infarction treatment is to prevent death and minimize damage to the heart. Treatment may include medications such as aspirin and statins to reduce the risk of another heart attack, procedures such as angioplasty and stenting to open blocked arteries, and lifestyle changes such as quitting smoking and eating a healthy diet.
Antiplatelet Agents:
Antiplatelet agents are a group of drugs that reduce the tendency of blood clots to form. Antiplatelet drugs can be used in patients suffering from lifestyle diseases such as obesity, diabetes, and high cholesterol levels. The antiplatelet agents market is expected to show lucrative growth over the forecast period owing to factors such as an increase in awareness about cardiovascular diseases & their treatment options and growing demand for safer medications with fewer side effects.
Glycoprotein IIb/IIIa Inhibitors:
Glycoprotein IIb/IIIa inhibitors are a new class of anti-inflammatory drugs that prevent the inflammatory response caused by glycoprotein IIb/IIIa. The drug is used to treat heart attacks and strokes caused by too much inflammation in the myocardium (heart muscle). Inflammation causes blood clots to form, which can block blood flow and cause a heart attack or stroke. The U.
Application Insights:
The hospital application segment dominated the global myocardial infarction treatment market in 2017. This can be attributed to factors such as availability of advanced healthcare facilities and highly skilled medical personnel. Moreover, increasing awareness about early treatment is expected to boost the demand for these drugs in this segment over the forecast period. In addition, a rise in prevalence of risk factors such as diabetes and obesity is anticipated to further increase the number of patients suffering from heart-related disorders requiring drug therapy. These aforementioned factors are likely to fuel market growth during the forecast period.
The clinic application segment is expected to witness substantial growth over the forecast period owing to rising awareness among individuals regarding availability of low cost effective therapies that do not require hospitalization at an outpatient facility or secondary care setting (such as cardiology clinics). Increasing initiatives by pharmaceutical companies for introduction of new products with reduced costs coupled with technological advancements are anticipated drive industry expansion during future years.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to favorable reimbursement policies, increasing prevalence of cardiovascular diseases, and availability of highly effective treatment options in this region. Moreover, presence of key pharmaceutical companies that are engaged in extensive R&D for development of novel drugs is also expected to contribute toward dominance during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income and improving healthcare infrastructure coupled with growing awareness about early diagnosis & management of cardiac disorders among people living in this region. Furthermore, increase in number majorly Chinese patients seeking medical care at foreign hospitals due to better quality services offered by these hospitals is further contributing toward regional growth. In addition, rise in investment by various governments for construction or upgradation of healthcare facilities will also boost demand during the forecast period as it will enable people access better treatment at a lower cost which benefits overall economic status quo thereby driving regional growth over the next eight years (2018-2030).
Growth Factors:
- Rising incidence of myocardial infarction (MI) due to changing lifestyle and unhealthy eating habits.
- Increasing awareness about the symptoms and risk factors of MI among people.
- Growing number of aging population susceptible to MI.
- Technological advancements in the diagnosis and treatment of MI resulting in better patient outcomes.
Scope Of The Report
Report Attributes
Report Details
Report Title
Myocardial Infarction Treatment Market Research Report
By Type
Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Others
By Application
Hospital, Clinic
By Companies
Bayer, Novartis, Daiichi Sankyo, Boehringer Ingelheim, Astrazeneca, Janssen Biotech, Merck, Sanofi, Pfizer, Bayer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
145
Number of Tables & Figures
102
Customization Available
Yes, the report can be customized as per your need.
Global Myocardial Infarction Treatment Market Report Segments:
The global Myocardial Infarction Treatment market is segmented on the basis of:
Types
Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Novartis
- Daiichi Sankyo
- Boehringer Ingelheim
- Astrazeneca
- Janssen Biotech
- Merck
- Sanofi
- Pfizer
- Bayer
Highlights of The Myocardial Infarction Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Antithrombotic Agents
- Others
- By Application:
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Myocardial Infarction Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Myocardial infarction (MI) is a heart attack. Treatment for MI includes medications to reduce the risk of another heart attack, surgery to remove the blockage in the artery that caused the heart attack, and/or treatment with stents to keep blood flowing through the artery.
Some of the key players operating in the myocardial infarction treatment market are Bayer, Novartis, Daiichi Sankyo, Boehringer Ingelheim, Astrazeneca, Janssen Biotech, Merck, Sanofi, Pfizer, Bayer.
The myocardial infarction treatment market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Myocardial Infarction Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Myocardial Infarction Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Myocardial Infarction Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Myocardial Infarction Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Myocardial Infarction Treatment Market Size & Forecast, 2018-2028
4.5.1 Myocardial Infarction Treatment Market Size and Y-o-Y Growth
4.5.2 Myocardial Infarction Treatment Market Absolute $ Opportunity
Chapter 5 Global Myocardial Infarction Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Myocardial Infarction Treatment Market Size Forecast by Type
5.2.1 Antiplatelet Agents
5.2.2 Glycoprotein IIb/IIIa Inhibitors
5.2.3 Antithrombotic Agents
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Myocardial Infarction Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Myocardial Infarction Treatment Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Myocardial Infarction Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Myocardial Infarction Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Myocardial Infarction Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Myocardial Infarction Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Myocardial Infarction Treatment Market Size Forecast by Type
9.6.1 Antiplatelet Agents
9.6.2 Glycoprotein IIb/IIIa Inhibitors
9.6.3 Antithrombotic Agents
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Myocardial Infarction Treatment Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Myocardial Infarction Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Myocardial Infarction Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Myocardial Infarction Treatment Market Size Forecast by Type
10.6.1 Antiplatelet Agents
10.6.2 Glycoprotein IIb/IIIa Inhibitors
10.6.3 Antithrombotic Agents
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Myocardial Infarction Treatment Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Myocardial Infarction Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Myocardial Infarction Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Myocardial Infarction Treatment Market Size Forecast by Type
11.6.1 Antiplatelet Agents
11.6.2 Glycoprotein IIb/IIIa Inhibitors
11.6.3 Antithrombotic Agents
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Myocardial Infarction Treatment Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Myocardial Infarction Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Myocardial Infarction Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Myocardial Infarction Treatment Market Size Forecast by Type
12.6.1 Antiplatelet Agents
12.6.2 Glycoprotein IIb/IIIa Inhibitors
12.6.3 Antithrombotic Agents
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Myocardial Infarction Treatment Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Myocardial Infarction Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Myocardial Infarction Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Myocardial Infarction Treatment Market Size Forecast by Type
13.6.1 Antiplatelet Agents
13.6.2 Glycoprotein IIb/IIIa Inhibitors
13.6.3 Antithrombotic Agents
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Myocardial Infarction Treatment Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Myocardial Infarction Treatment Market: Competitive Dashboard
14.2 Global Myocardial Infarction Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer
14.3.2 Novartis
14.3.3 Daiichi Sankyo
14.3.4 Boehringer Ingelheim
14.3.5 Astrazeneca
14.3.6 Janssen Biotech
14.3.7 Merck
14.3.8 Sanofi
14.3.9 Pfizer
14.3.10 Bayer
